Solasia Pharma K.K., a specialty pharmaceutical company, develops, imports/exports, and markets pharmaceutical products and medical devices, etc. in Japan. It offers SP-01 Sancuso, a transdermal delivery system that delivers the anti-emetic and granisetron into the patient’s bloodstream to patients receiving chemotherapy; and SP-02 Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, as well as SP-03 episil, an oral liquid for the treatment of pain associated with oral mucositis. The company was founded in 2006 and is based in Tokyo, Japan.